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Abstract: The Epstein–Barr nuclear antigen 3 (EBNA3) family of proteins, comprising EBNA3A,
EBNA3B, and EBNA3C, play pivotal roles in the asymptomatic persistence and life-long latency of
Epstein–Barr virus (EBV) in the worldwide human population. EBNA3-mediated transcriptional
reprogramming of numerous host cell genes promotes in vitro B cell transformation and EBV
persistence in vivo. Despite structural and sequence similarities, and evidence of substantial
cooperative activity between the EBNA3 proteins, they perform quite different, often opposing
functions. Both EBNA3A and EBNA3C are involved in the repression of important tumour
suppressive pathways and are considered oncogenic. In contrast, EBNA3B exhibits tumour
suppressive functions. This review focuses on how the EBNA3 proteins achieve the delicate balance
required to support EBV persistence and latency, with emphasis on the contribution of the Allday
laboratory to the field of EBNA3 biology.
Keywords: Epstein–Barr virus; EBNA3 proteins; epigenetic regulation; viral oncogenes; viral tumour
suppressor; CDKI regulation
1. Epstein–Barr Virus
The lymphotropic gamma-herpesvirus Epstein–Barr virus (EBV) asymptomatically and
persistently infects the majority of the worldwide human population. Despite being a ubiquitous virus,
it is one of the most transforming viruses identified, and is aetiologically associated with a variety of B
cell malignancies, including Burkitt’s lymphoma (BL), Hodgkin’s lymphoma (HL), and diffuse large
B cell lymphoma (DLBCL), alongside post-transplant lymphoproliferative disease, nasopharyngeal
carcinomas, and some gastric carcinomas [1]. Upon infection of mature B lymphocytes in vitro, EBV
efficiently induces transformation of B cells into continuously proliferating lymphoblastoid cell lines
(LCLs). These LCLs express nine latency associated viral proteins; there are six nuclear antigens
(EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP) and three latent membrane proteins
(LMP1, LMP2A, and LMP2B), alongside several RNA species [2]. In vivo, the biology of EBV is
intimately linked to that of B cell differentiation. It is thought that EBV infection drives naïve B cells
to proliferate and differentiate into activated B-blasts, which phenotypically resemble LCLs. These
activated B-blasts then migrate through germinal centres where they further differentiate, resulting in
resting memory B cells that carry the EBV genome as extra-chromosomal episomes, forming long-lived
reservoirs of EBV infection [3]. During transition through the germinal centre there is a sequential
silencing of viral gene expression, so that no viral proteins are expressed in resting memory B cells [2].
2. The EBNA3 Family
The latency-associated EBNA3 family of proteins comprises 3 large proteins called EBNA3A,
EBNA3B, and EBNA3C, each composed of over 900 amino acids. These non-redundant proteins
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are thought to have arisen from tandem duplication events during the evolution of old world
lymphocryptoviruses. Their genes are structurally similar, with each consisting of a short 5′ coding
exon and long 3′ coding exon, and share limited but significant sequence homology. Each of the
EBNA3 proteins features a proline rich region, as well as a “homology domain” of approximately
220–230 amino acids near the N-terminus, in which there is 20–30% identity between the EBNA3s
(Figure 1, [4,5]). The EBNA3s are predicted to share similar secondary structures, despite having only
modest homology overall [4]. EBNA3 mRNA transcripts are initiated from the Cp latency promoter
producing large, alternatively spliced mRNAs that are only expressed in B cells. Production of EBNA3
proteins is thought to be tightly regulated, and the proteins are very stable, as protein levels and
turnover are low [6,7].
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Figure 1. Schematic showing structure of the homology domain between the Epstein–Barr virus (EBV)
EBNA3 family of proteins. Numbers denote amino acid position within the prototype strain B95.8 protein.
EBV recombinant viruses containing various EBNA3 genetic modifications have been generated
using bacterial artificial chromosome (BAC) technology, allowi g detailed study of the EBNA3
proteins in the context of infection, B c ll transformation and maintenance of viral la e cy. EBNA3
knockouts (KO) have been generated using mutations and deletions [8,9], alongside conditional
systems. These conditional systems use an oestrogen receptor fused to the open reading frames
of EBNA3A and/or EBNA3C, making functional expressio dependent on the activating ligand
4-hydroxytamox fen (HT). The HT tabilises the fusion p ot in, allowing nuclear localisation and
functional expression [10–14]. Epitope tagged EBNA3 fusion genes in EBV BACs have been used in
chromatin immunoprecipitation sequencing (ChIP-seq) experiments to identify thousands of EBNA3
binding sites across the genome [15–18].
EBNA3 proteins are w ll characterised re l t rs of transcription. Exon-microarray analysis using
the EBV-negative Burkitt’s lymphoma (BL) cell line BL31 infected with mutant EBNA3 viruses revealed
that the EBNA3 proteins transcriptionally regulate over 1000 host cell genes. A substantial number of
these genes show cooperative regulation between multiple EBNA3 proteins. Most of this co-regulation
involves EBN worki g in co peration with either EBNA3A or EBNA3B or both, with only modest
cooperation between EBNA3A and EBNA3B in the absence of EBNA3C. Moreover, deletion of EBNA3C
had the most significant impact on host gene regulation, with gene repression dominating differential
host gene expression [8]. ChIP analysis demonstrated that EBNA3A and EBNA3C have significant
colocalisation across the genome, as do EBNA3B and EBNA3C. However, colocalisation of EBNA3A
and EBNA3B in the absence of EBNA3C was extremely rare [18]. EBNA3 proteins do not bind to DNA
directly, instead, transcriptional regulation is achieved through interactions with cellular DNA binding
factors (see Section 3).
Both EBNA3A and EBNA3C are considered oncogenic. In an early demonstration of this,
EBNA3C was shown to cooperate with oncogenic (Ha-)Ras during transformation of primary rat
embryo fibroblasts [19]. The oncogenic functions of EBNA3A and EBNA3C differ from the seemingly
antagonistic EBNA3B, despite clear cooperative regulation of a variety of genes [20]. Alongside
EBNA1, EBNA2, EBNA-LP, and LMP1, both EBNA3A and EBNA3C are required for the efficient
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transformation of B cells [21–25]. EBNA3C is essential for B cell transformation, and EBNA3A
is important, with EBNA3A-null cell lines exhibiting reduced proliferative capacity [10,12,14,26].
In contrast to the necessity of EBNA3A and EBNA3C for efficient B cell immortalisation, EBNA3B
is completely dispensable for the transformation of B cells in vitro, and appears to act as a tumour
suppressor in vivo ([27], see Section 7).
3. EBNA3 Regulatory Mechanisms
3.1. Recruitment
Although the EBNA3 proteins regulate many target genes and robustly associate with chromatin,
they do not bind DNA directly. Instead, the EBNA3 proteins bind many cell transcription factors to
facilitate viral regulation of host genes. Of these factors, the Notch signalling pathway DNA-binding
factor RBP-Jκ (also called CBF1) was the first to be identified as a binding partner for all EBNA3s [28,29],
with the interaction mapped to the EBNA3 homology domain (See Figure 1, [2,28,30,31]). RBP-Jκ
is also bound by the EBV transactivator EBNA2 in a mutually exclusive manner to the EBNA3s,
suggesting some interplay of functions [32]. In transient reporter assays, each EBNA3 was able to
inhibit activation of viral promoters LMP2A and Cp by EBNA2, indicating the importance of RBP-Jk
in EBNA3 function, and showing EBNA3s to be transcriptional regulators [5,29,33,34]. This led to
the hypothesis that RBP-Jκ is the recruiter of the EBNA3s to chromatin. The importance of RBP-Jk
was further corroborated when it was shown that interaction of RBP-Jκ with EBNA3A and EBNA3C
is required to achieve the genetic reprogramming of B cells that allow continuous proliferation of
LCLs [35–37]. The mechanism for this is still unclear.
RBP-Jκ is, however, absent from many known EBNA3 binding sites as revealed by ChIP-seq
experiments exploring EBNA3 genome-wide localization [16–18,38,39]. In addition, at sites where
RBP-Jk was present, it was shown to be dynamically recruited to chromatin concurrently with
EBNA3C [30]. The same studies also revealed that the EBNA3s bind at sites containing binding
motifs for other transcription factors, or sites where numerous transcription factors are known to bind
(e.g., PU.1, EBF1, RUNX3, BATF, IRF4), potentially recruiting the EBNA3s there. IRF4 has been shown
to be important for EBNA3C recruitment on to chromatin, by assessing localization of exogenously
expressed EBNA3A, EBNA3B, or EBNA3C in cells either lacking or expressing IRF4 [39]. In a separate
study, it was shown that EBNA3C and EBNA3B (and to a lesser extent EBNA3A) all bind to core
binding factor β (CBFβ), which heterodimerizes with the transcription factor RUNX3 to form the core
binding factor (CBF). EBNA3 binding to target gene loci was reduced when CBF was depleted by
shRNA against CBFβ, indicating its importance for EBNA3 recruitment to chromatin [18]. So far there
is direct evidence for only these two transcription factors (IRF4 and CBF), mediating recruitment of
EBNA3B and/or EBNA3C. It is unknown whether they are the only ones, and unclear whether they
act independently at different sites, or cooperatively at sites, where both bind together with EBNA3C.
IRF4, and to a lesser extent EBF1, were also recently shown to be important in recruitment of EBNA3A to the
EBNA3A-regulated locus STK39 [40]. It is currently unclear whether this effect is independent of EBNA3C.
3.2. Changes in Chromatin Architecture
All EBNA3s localise to chromatin with histone marks characteristic of enhancer elements [16–18,38,39],
indicating that long distance chromatin interactions are a prominent feature of gene regulation by
EBNA3. EBNA3 binding sites found distal to promoters of regulated genes (CXCL10/CXCL9 [41],
ADAM28/ADAMDEC1 [38]) further corroborated this, and EBNA3-mediated chromatin looping
was eventually directly shown by chromosome conformation capture experiments for EBNA3A
and EBNA3C (reviewed in [32]). Specifically, EBNA3C, and in part, EBNA3A, are thought to
facilitate repression of the ADAM28-ADAMDEC1 locus by promoting a long-range interaction between
an intergenic enhancer and their respective promoters [30,38]. Additionally, EBNA3C promotes
chromosome looping between the downstream enhancer and promoter of WEE1, leading to gene
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repression [38]. In contrast, BCL2L11 (BIM) and CTBP2 repression are thought to result from
EBNA3-mediated disruption of enhancer–promoter interactions [38,42]. Furthermore, EBNA3A and
EBNA3C can also activate transcription by promoting chromosome looping between distal enhancer
elements and the transcription start site of the pri-miRNA of the miRNA 221/222 cluster [12]. Together,
these observations suggest that EBNA3C and probably EBNA3A can both engage and disrupt long
range chromatin interactions, and that these structural changes can either enhance or repress gene
transcription, probably in ways that can only be ascertained on a gene-by-gene basis.
3.3. Repressors and Activators
The ability of the EBNA3s to mediate both host gene activation and repression was clear from a
series of microarray experiments that interrogated the transcriptional profile of cells with or without
expression of each EBNA3 [8,26,43]. This is despite results from transient reporter assays mentioned
above that suggested all EBNA3s are repressors. For EBNA3A/EBNA3C [12] and EBNA3C [30],
direct transcriptional activation of host genes has been shown, but not for EBNA3B. Not surprisingly,
EBNA3A and EBNA3C binding sites have been identified within ”contact domains” (genomic regions
shown to come into contact through looping) of both up- and downregulated target genes. In contrast,
EBNA3B binds significantly only within contact domains of genes identified as downregulated by
EBNA3B, suggesting that EBNA3B functions directly only as a repressor [18].
How the different outcomes of repression or activation are determined for EBNA3A and EBNA3C
is unclear. One could envisage that the EBNA3 proteins act always in the same way, and the
chromatin context of each gene determines the outcome, but this has not yet been shown. It seems
that the outcome of looping (i.e., facilitation or disruption of looping) is not the only determinant.
There can be facilitation of looping and two different outcomes, for example, miRNA221/222 with
activation [12] and ADAM28/ADAMDEC1 with repression [38]; in both these cases, EBNA3A and
EBNA3C regulate. There can also be repression by either facilitation or disruption of looping,
notably at ADAM28/ADAMDEC1 with facilitation, and at BCL2L11 with disruption [38], under
EBNA3A/EBNA3C regulation.
3.4. EBNA3 Interactors That Facilitate Regulation
Regulatory mechanisms of EBNA3C are much better characterised than those of EBNA3A,
and less is known about EBNA3B, with the current lack of an EBNA3B-ERT2 conditional virus limiting
investigation. Part of their action is explained by their antagonism with the viral transactivator EBNA2
for binding to RBP-Jκ. This, however, is not the whole story, because of EBNA3 binding elsewhere
and EBNA3A and EBNA3C also acting as activators themselves. Several transcription cofactors that
could facilitate regulation have been found to interact with EBNA3A and EBNA3C. These include the
histone deacetylases (HDAC1 and HDAC2) and the co-repressor CtBP for EBNA3A, and HDAC1/2,
CtBP, SIN3 transcription regulator family member A (SIN3A), nuclear receptor co-repressor (NCoR)
and histone acetyltransferase p300 for EBNA3C [44–48]. Of these, only CtBP has been confirmed to
be directly involved in EBNA3-mediated gene repression by genetic analysis using recombinant EBV
viruses expressing mutant EBNA3A and/or EBNA3C that cannot bind to CtBP. Here, the requirement
for CtBP interaction was demonstrated for EBNA3-mediated repression of p16INK4a in B cells, but the
mechanistic basis of this requirement remains uncertain [10].
The p300 histone acetyltransferase is a co-activator, and its association with EBNA3C might
explain EBNA3C’s ability to activate. Enrichment of p300 at EBNA3C-activated gene AICDA was
found in response to EBNA3C presence [49], but more EBNA3 activated genes will have to be studied
to clarify whether additional undiscovered factors may also contribute.
HDACs, NCoR, and SIN3A are generally thought of as repressors, and are all associated
with histone deacetylation—a primary epigenetic mark associated with repression. In all cases
of EBNA3-mediated repression investigated on a gene-by-gene basis, histone deacetylation has
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been observed. Importantly, when the process of histone deacetylation was tracked together with
establishment of repression, they were found to be concurrent [30,41].
EBNA3-mediated gene silencing through association with transcription factors often involves
localising polycomb repressive complexes 1 and 2 (PRC1, PRC2) to target genes. Interestingly,
PRC1 component BMI1 was found to be recruited to genes during establishment of repression,
with kinetics that matched those of histone deacetylation, suggesting that it might be important
at the initial stage [30]. BMI1 knockdown has also been shown to lead to de-repression of the
EBNA3A/3C-repressed gene BIM [15], although it should be noted that PRC1 has also been implicated
in gene activation [50]. It remains to be shown if this is relevant in the EBNA3 context.
In contrast to PRC1, the involvement of PRC2 in repression of EBNA3 target genes is well
established, and can often result in deposition of the repressive histone mark H3K27me3, catalysed by
the methyltransferase subunit (EZH2) of PRC2 [10,13,15,30,40,41,51,52]. However, ChIP-seq analyses
have shown that H3K27me3 colocalises with very few EBNA3 binding sites. In addition, H3K27me3
deposition was found to lag behind establishment of repression, suggesting that this epigenetic
mark is a consequence, rather than the driver of initial repression in these cases [30,41]. This lag
might also explain why for most EBNA3-regulated genes the timeframe of regulation is several
days, with differently timed waves of epigenetic marks that have an additive effect. The additive
effect of H3K27me3 in repression has been suggested by knockdown of PRC2 component SUZ12 or
treatment with an inhibitor of EZH2 (the catalytic subunit of PRC2)—both causing de-repression [15,42].
Importantly, a recent study of the STK39 gene (the only gene described in detail so far that is solely
repressed by EBNA3A) showed that PRC2 and H3K27me3 are important for the initial establishment
of repression [40].
The apparent complexity of EBNA3 mechanisms of action is probably the result of the many
transcription factors they seem to interact with. Regardless, general principles have emerged. Their
association with chromatin is usually mediated by more than one DNA-binding transcription factor,
probably in a locus-specific manner. They are mostly recruited to enhancer elements, distal to the
promoters they regulate, which means that changes in chromatin architecture are necessary for their
action. This can be either by enhancing or disrupting chromatin loop formation. There is evidence for
direct activation only by EBNA3A and EBNA3C, whereas EBNA3B seems to act only as a repressor.
The regulation they confer is epigenetic, primarily through changes in histone acetylation, which in
some cases lead to changes in histone methylation with additive effects on repression.
4. EBNA3A and EBNA3C Regulate Anti-Proliferative and Tumour Suppressive Pathways
A complex system of phosphorylation and feedback loops regulates cell division to prevent
aberrant proliferation and cancer progression. EBNA3A and EBNA3C have been shown to circumvent
these pathways by interfering with intrinsic cell cycle associated factors that prevent anti-proliferation
and suicidal response pathways. The best characterised is EBNA3A- and EBNA3C-mediated repression
of various cyclin-dependent kinase inhibitors (CDKIs) [20]. Deregulation of the complex and tightly
coordinated molecular machinery that controls the cell cycle, mediated through the concerted activity
of EBNA3A and EBNA3C, likely plays a vital role in efficient EBV-mediated B cell transformation and
subsequent viral persistence [43,53].
4.1. Direct Epigenetic Repression of the Tumour Suppressor and CDKI p16INK4a
EBV-mediated repression of the CDKI and tumour suppressor p16INK4a was first shown using
a recombinant virus containing EBNA3C fused to oestrogen receptor. This showed that functional
EBNA3C is essential to restrain expression of p16INK4a [11]. Inactivation of EBNA3C in conditional
LCLs leads to progressively increased levels of p16INK4a mRNA and protein, with correspondingly
reduced levels of hyperphosphorylated forms of the retinoblastoma protein (Rb), a cessation of
proliferation, and more cells in the G1 phase of the cell cycle [10,11,43]. Increased p16INK4a levels
were ablated by transfection of a plasmid expressing EBNA3C and by stabilisation of the conditional
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EBNA3C [11]. The CDKN2A gene encodes p16INK4a, and also (by an alternative reading frame)
encodes p14ARF, which is also repressed by EBNA3C [54]. However, the consequences are functionally
distinct. The p16INK4a protein interacts with the cyclin dependent kinases CDK4 and CDK6, preventing
phosphorylation of the retinoblastoma (Rb) protein leading to cell cycle arrest, whereas p14ARF interacts
with MDM2, resulting in p53 activation and subsequent cell cycle arrest or apoptosis [55]. Analysis
of EBNA3A knockout and conditional LCLs has demonstrated that EBNA3A also plays a role in
repressing both p16INK4a and p14ARF [10,26,54]. There is a cumulative effect on p16INK4a when both
EBNA3A and EBNA3C are inactivated, with elevated levels of p16INK4a mRNA compared to when
EBNA3A or EBNA3C are inactivated independently [13]. The importance of p16INK4a repression
during B cell transformation by EBV was highlighted by evidence that EBNA3C becomes unnecessary
for transformation and sustained proliferation when p16INK4a is functionally inactive. In an elegant
experiment, Skalska et al. showed that EBNA3C-null LCLs can be readily produced from B cells
derived from an individual with a homozygous deletion in CDKN2A that inhibits all known p16INK4a
functions. This demonstrated that EBNA3C-mediated repression of p16INK4a plays a crucial role in the
transformation of B cells by EBV [43].
ChIP analysis indicates EBNA3A and EBNA3C directly repress p16INK4a through epigenetic
chromatin modification, via deposition of the polycomb-associated repressive mark H3K27me3,
and reduction of the activation mark H3K4me3 at the CDKN2A locus [10,54]. Moreover, epigenetic
regulation of CDKN2A by EBNA3s is maintained in the absence of functional p16INK4a, further
indicating CDKN2A is a direct target of EBV [43]. The chromatin remodelling of CDKN2A by EBNA3A
and EBNA3C was shown to require interaction with the transcriptional co-repressor CtBP [10].
CtBP is the collective term for the proteins CtBP1 and CtBP2, which promote cell survival and
are associated with repression of various tumour suppressors (as reviewed in [56]). EBNA3A
and EBNA3C, but not EBNA3B, have been shown to interact with CtBP, and they are readily
immunoprecipitated together from LCL extracts [44,47]. Mutating the CtBP binding sites within
EBNA3A and EBNA3C compromises transformation of primary B cells infected with recombinant
EBV, and similarly compromises transformation of rodent embryo fibroblasts following transfection
with EBNA3A or EBNA3C [10,44,47]. In B cells, mutation of CtBP binding sites within EBNA3A and
EBNA3C correlates with significantly reduced H3K27me3 at the CDKN2A locus, alongside increased
H3K4me3. The resulting increases in p16INK4a mRNA and protein are thought to contribute to the
impaired outgrowth of primary B cells infected with EBV containing mutated CtBP binding sites in
EBNA3A and EBNA3C, and the reduced proliferative capacity of resulting LCLs [10].
Alongside CDKN2A, EBNA3 proteins have also been shown to repress the adjacent gene CDKN2B.
This gene encodes the related INK4 family protein p15INK4b, which performs similar functions to
p16INK4a [55]. EBNA3A-mediated transcriptional repression was shown to occur via interactions with the
transcriptional factor MIZ1, leading to subsequent deposition of the repression histone mark H3K27me3
in close proximity to the transcription start site, as seen with p16INK4a repression [43,57]. Furthermore,
increased p15INK4b mRNA transcription has been reported following EBNA3C inactivation in
conditional systems, demonstrating EBNA3C involvement in p15INK4b repression [13,58]. As with
CDKN2A, ChIP analyses have indicated EBNA3A and EBNA3C bind near the transcription start
sites of the CDKN2B locus, suggesting EBNA3A and EBNA3C play a direct repressive role [16,43,58].
In addition to p15INK4b and p16INK4a, EBNA3A and EBNA3C have also been shown to repress the
INK4 family member p18INK4c through PRC2-mediated deposition of H3K27me3 ([13]).
4.2. EBNA3A- and EBNA3C-Mediated Transactivation of Oncogenic miRNAs That Target CDKIs
As well as directly repressing genes of the CDKI INK4 family, EBNA3A and EBNA3C can
indirectly repress cell cycle components through transcriptional activation of repressive microRNA
(miR). EBNA3A and EBNA3C were recently shown to mediate transactivation of the oncogenic miR
cluster miR221 and miR222 (miR221/222), leading to repression of the CDKI p57KIP2, and to a lesser
extent, p27KIP1 [12].
Pathogens 2018, 7, 31 7 of 15
Screening LCLs, where EBNA3A and EBNA3C were either conditionally expressed or knocked
out, identified modified expression of various miRNAs by the EBNA3 proteins. Expression of the
oncogenic miR221/222 cluster was shown to be reduced when either EBNA3A or EBNA3C was
non-functional, with a significant increase in miR221/222 mRNA when EBNA3A and EBNA3C were
conditionally activated. ChIP analysis confirmed EBNA3A and EBNA3C binding sites within an
enhancer element of the pri-miR221/222 locus, from which miR221 and miR222 are processed. ChIP
analysis further revealed an altered epigenetic profile in which the transcriptional activation markers
H3K4me3, H3K9ac, H3K27ac, and phospho-Ser5 Pol II were elevated at the transcription start site only
when EBNA3A and EBNA3C were functionally expressed. Furthermore, chromosome confirmation
capture established that long range chromatin interactions between EBNA3A and EBNA3C binding
sites within the predicted enhancer site of pri-miR221/222 and its promoter only occur when EBNA3A
and EBNA3C are functionally active. The miRNA221/222 cluster targets the CDKIs p57KIP2 and
p27KIP1; transcriptional activation of the miRNAs by EBNA3A and EBNA3C leads to repression of
p57KIP2, and to a lesser extent, p27KIP1. This provides a novel indirect method of cell cycle regulation
mediated by EBNA3A and EBNA3C gene activation [12].
Alongside indirect repression of p27KIP1 and p57KIP2, EBNA3A and EBNA3C have also been
associated with repression of the CDKI and CIP/KIP family member p21WAF1/CIP1 [59,60]. In contrast
to the direct polycomb-mediated transcriptional repression of the INK4 proteins, or miRNA-mediated
translational regulation of p57KIP2 and p27KIP1, EBNA3C works directly though interactions with
the oncogenic kinase Pim-1 to result in proteasomal degradation of p21WAF1/CIP1 [59]. There is
compelling evidence that transcriptional repression of p16INK4a is the dominant factor in EBNA3A-
and EBNA3C-mediated cell cycle control during B cell transformation by EBV [43]. However, EBNA3A
and EBNA3C have been shown to target many CDKIs, employing diverse mechanisms that encompass
regulation at the transcriptional, translational, and protein level (summarised in Figure 2). This
suggests the EBNA3 proteins function to achieve a specific molecular balance that allows control of the
cell cycle by EBV, enabling establishment of viral latency.
Figure 2. EBNA3A and EBNA3C regulate CDKI at a transcriptional, translational, and protein levels.
EBNA3A and EBNA3C bind cell transcription factors (TFs) including RBP-Jκ, CBF, and IRF4. This results in
polycomb complex recruitment and deposition of chromatin marks on the loci of target genes. These chromatin
marks can either repress transcription (the CDKIs p16INK4a, p15INK4b, and p18INK4c) or activate transcription
(miRNA221/222). EBNA3-mediated activation of miRNA221/222 leads to subsequent repression of the
CDKI p27KIP1 and p57KIP2 via translation inhibition. EBNA3A and EBNA3C can also repress CKDI by
targeting them for degradation. EBNA3A mechanisms are unclear, but EBNA3C has been shown to mediate
Pim-1 catalysed phosphorylation and subsequent proteasomal degradation of p21WAF1/CIP1.
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5. Anti-Apoptotic Functions of EBNA3A and EBNA3C
Concurrent with manipulation of CDKI and cell cycle control, EBNA3A and EBNA3C further
facilitate virally-induced proliferation and oncogenesis by repressing apoptotic responses to viral
infection and transformation. Using a panel of EBNA3KO viruses in BL31 BL-derived cells,
EBNA3A and EBNA3C were found to cooperatively repress the tumour suppressor and pro-apoptotic
BCL-2-family member BIM (Bcl-2-interacting mediator of cell death) encoded by BCL2L11 [9].
EBNA3-mediated regulation of BIM was also observed in LCLs, with repression shown to be reversible
using an EBNA3C conditional system, whereby inactivating EBNA3C for three weeks led to elevated
BIM mRNA levels [15,43]. BIM becomes upregulated during unscheduled cellular proliferation
and directly initiates apoptosis through inhibition of BCL2 and other pro-survival proteins. This is
particularly important during the development of lymphocytes, as BIM mediates negative selection of
auto-reactive B cells, and initiates programmed cell death in B cells expressing low-affinity antibodies
in the germinal centre [61–63]. Furthermore, BIM is activated by the protooncogene MYC, which is
expressed by B cells following EBV infection and induces hyperproliferation. A hallmark of BL is
translocation of MYC and subsequently constitutively elevated expression [64]. BIM is the effector of
one of the accumulative apoptotic pathways triggered by MYC overexpression (the other being the
p14ARF–MDM2–p53 pathway) and it has been shown that even loss of a single BIM allele accelerates
B lymphomagenesis [65]. The epigenetic mode of BIM repression by EBNA3A and EBNA3C may
be important for Burkitt’s lymphoma development, since it can create an environment permissive
for MYC overexpression, even after EBNA3A and EBNA3C expression is shut down, as the virus
progresses through different stages of latency [9,66,67].
Analogous with the epigenetic repression of INK4 family proteins, detailed ChIP analysis of
EBV-positive B cells indicated that EBNA3-mediated repression of BIM involves modification of
chromatin marks. This includes a reduction of histone acetylation and deposition of the H3K27me3
repressive mark within the BCL2L11 locus, facilitating transcriptional repression [66]. Direct
participation of EBNA3 proteins in repression of BIM was subsequently demonstrated when binding
of EBNA3C to sites proximal to the BCL2L11 transcriptional start site was confirmed by ChIP analysis,
with later studies showing concurrent EBNA3A binding sites [15,42]. Furthermore, EBNA3A and
EBNA3C were found to recruit the PRC2 subunits SUZ12 and EZH2 to BIM regulatory elements,
facilitating H3K27me3 deposition [15]. A requirement for the polycomb system in EBV-mediated
repression of BIM was further confirmed as BIM repression was found to be disrupted by lentiviral
delivery of shRNA against PRC2 components, and reversed by an EZH2 inhibitor [15,42]. EBNA3A-
and EBNA3C-mediated repression of BIM was also recently shown to involve long range chromatin
interactions between the BIM promoter and enhancers bound by EBNA3A and/or EBNA3C [42].
In addition to EBNA3A- and EBNA3C-mediated repression of the important tumour suppressors
p16INK4a and BIM, alongside others mentioned in this article, EBNA3C has been shown to attenuate the
DNA damage response (DDR), which functions to limit aberrant proliferation by inducing senescence
and apoptosis [68]. The DDR is transiently activated in response to the hyperproliferation of EBV
infected cells during primary infection. However, EBNA3C was shown to attenuate this response
by inhibiting the DDR kinases CHK2 and ATM [68]. Induction of the DDR temporally correlates
with the transient increase in p16INK4a expression seen following primary infection [43]. This is
associated with oncogene activation, but is also speculated to be a consequence of DNA damage due
to hyperproliferating cells inappropriately entering the cell cycle S phase [43,53]. The continuation
of the DDR, as well as p16INK4a and BIM activation, is subsequently prevented by the expression of
functional EBNA3C and EBNA3A, which help to prevent apoptosis and cell cycle arrest pathways
and allow outgrowth of LCLs [43,53,68]. Furthermore, EBNA3C has also been associated with the
repression of other factors involved in the cell cycle, DNA damage response, apoptotic pathways and
the oncogenic stress response, including MDM2, p53, H2AX, pRb, E2F1, Cyclin A, ubiquitin ligase
SCFSKP2 and c-Myc [69–76]. This well-documented oncogenic activity of both EBNA3A and EBNA3C
is in stark contrast to the functions of the third EBNA3 protein, EBNA3B.
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6. EBNA3B: The Antagonistic Tumour Suppressive EBNA3 Protein
Despite structural and partial sequence homology, EBNA3B has distinctly different functions
from those of the oncogenic EBNA3A and EBNA3C. It is completely dispensable in vitro, and B cells
infected with EBV in the absence of EBNA3B exhibit elevated proliferative capacity compared to
WT [20,27,77]. This phenotype contrasts with that of the reduced efficiency of B cell transformation by
EBNA3A-null EBV and the inability of EBNA3C-null EBV to cause LCL outgrowth [14,23,26,43].
In contrast to the oncogenic functions of EBNA3A and EBNA3C, EBNA3B appears to have
tumour suppressive activity in vivo [27]. In NOD-scid-IL2Rγnull mice engrafted with human immune
system components, which are susceptible to EBV infection, those infected with EBNA3B-KO
exhibited increased splenomegaly and a higher frequency of large tumour masses than WT and
EBNA3B-revertant infections after four weeks. These tumours destroyed splenic architecture, and by
immunohistochemistry were monomorphic and highly proliferative, resembling the activated B cell
(ABC) subtype of DLBCL. Furthermore, tumours derived from EBNA3B-deficient infections lacked
infiltrating T cells. This was despite these infections priming a stronger systemic immune response
compared to WT and revertant virus infections, with a higher percentage of splenic T cells, including
CD8+ve T cells capable of killing EBV-positive cells in vitro [27]. This is potentially a result of an absence
of EBNA3B-mediated activation of the T cell migratory chemokine CXCL10, although microarray
studies have identified other chemokine, chemokine receptor, and integrin genes whose expression is
altered in EBNA3B-KO LCLs that could also contribute to the exclusion of T cells from the tumour [8,27].
Together, this indicates that EBNA3B plays a role in immunological trafficking and T cell surveillance
of tumours. Furthermore, EBV-positive ABC-DLBCL with non-sense mutations in the EBNA3B gene,
and BL and HL with in frame deletions, have also been identified in humans, suggesting that EBV
mutations can contribute to occurrence of these cancers [27].
Despite the seemingly opposite basic functions of EBNA3B compared to EBNA3A and
EBNA3C, EBNA3B cooperatively regulates some genes with EBNA3C, sometimes with the additional
contribution of EBNA3A [8]. This is consistent with the extensive colocalisation of the EBNA3 proteins
across the genome [18]. The EBNA3 proteins, working independently and in combination, seem
to provide a complex balance during infection between the pro-proliferative functions of EBNA3A
and EBNA3C, against the seemingly anticancer functions of EBNA3B. This compromise between the
EBNA3 proteins has likely evolved to minimise the oncogenic risk to latent carriers while establishing
persistence within the population.
7. Suppression of Plasma Cell Differentiation: An Additional Role for the Oncogenic
EBNA3 Proteins
Aside from manipulating regulation of cell cycle factors, microarray analysis has also indicated
that EBNA3 proteins may alter the regulation of various factors associated with B cell differentiation [8].
Recently, insight into this alternative EBNA3 function was demonstrated when EBNA3A and EBNA3C
were shown to directly epigenetically repress the CDKI and plasma cell differentiation factor p18INK4c,
encoded by CDKN2C [13,78–80], and BLIMP-1, the major transcriptional regulator of plasma cell
differentiation and tumour suppressor, encoded by PRDM1 [13,81–83].
Using a recombinant virus, in which EBNA3A and EBNA3C are both expressed conditionally,
simultaneous inactivation of EBNA3A and EBNA3C during primary B cell infection was shown to lead
to elevated levels of p18INK4c and BLIMP-1 mRNA and protein [13]. In contrast to the INK4 proteins
p15INK4b and p16INK4a, functional expression of either EBNA3A or EBNA3C individually is largely
sufficient to repress p18INK4c and BLIMP-1 transcription [13,43,54,58]. The increased levels of p18INK4c
and BLIMP-1 in EBNA3A/EBNA3C-null cells were physiologically comparable to those of plasma cell
models, and transcription of the BLIMP-1 target genes XBP-1, LMO2, and SPIB responded as expected
to the elevated BLIMP-1 levels. Concurrent with the roles of p18INK4c and BLIMP-1 in promoting
plasma cell differentiation, flow cytometric analysis of EBNA3A/EBNA3C-null cells showed the
development of a plasma cell-like phenotype, with elevated surface markers characteristic of plasma
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cells, including CD138 and CD38, alongside elevated IgG and IgM expression. This indicates that
EBNA3A and EBNA3C have evolved, not only as oncogenic factors, but also as repressors of plasma
cell differentiation [13]. This is likely a mechanism to promote transition of activated B-blasts through
the germinal centre and subsequent differentiation of memory B cells, allowing establishment of the
long-lived reservoirs of EBV within latently infected individuals [3].
As with the BCL2L11, CDKN2A, and CDKN2B loci, ChIP analysis showed EBNA3A and EBNA3C
bind around the transcriptional start sites of the CDKN2C (p18INK4c) and PRDM1 (BLIMP-1) genes,
where they mediate deposition of H3K27me3 catalysed by the EZH2 component of the PRC2 complex.
This leads to stable epigenetic reprogramming of these plasma cell differentiation associated genes [13].
In contrast to EBNA3-mediated repression of BIM, p15INK4b and p16INK4a, which can be reversed by
inactivation of either EBNA3A or EBNA3C, regulation of p18INK4c and BLIMP-1 was shown to be
irreversible by eight days post infection, with inactivation of EBNA3A and EBNA3C failing to lead
to reactivation of either gene, even after thirty days [10,13,15,43,54]. The mechanisms responsible
for the irreversible epigenetic reprogramming of p18INK4c and BLIMP-1 by EBNA3 proteins are
presently unknown, but may involve additional chromatin modifications. The differential regulation
of these target genes highlights the complexity of EBNA3A and EBNA3C appropriation of the
polycomb system.
EBNA3A- and EBNA3C-mediated repression of the plasma cell differentiation factors p18INK4c
and BLIMP-1 appears to be independent of EBNA3B [13]. However, microarray analysis of BL31
BL-derived cells suggests a distinct role for EBNA3B in B cell differentiation, as its deletion leads to
upregulation of a subset of genes usually repressed in the germinal centre [8]. This suggests EBNA3B
may contribute to the progression of EBV-infected cells through the germinal centre reaction, therefore
helping facilitate memory B cell differentiation. While the role of EBNA3B in this capacity has not been
investigated, it is possible that all of the EBNA3 proteins are directing differentiation towards the site
of long-term latency.
8. Summary
The complex cooperative and antagonistic functions of the EBNA3 proteins, encompassing the
critical epigenetic reprogramming of target genes, are central to achieving EBV persistence and latency.
EBV infection stimulates proliferation of infected B cells to facilitate differentiation. This aberrant
cell proliferation is permitted due to EBNA3A- and EBNA3C-mediated repression of cell cycle arrest
pathways and suppression of pro-apoptotic signals. As B cell differentiation may lead to plasma
cells, EBV must also promote transition through the germinal centre to achieve latency in memory B
cells. EBNA3A and EBNA3C thus also suppress plasmacytoid differentiation, supporting the creation
of a long-lived reservoir of EBV-infected memory B cells. It is possible that this process is further
supported by EBNA3B, through T cell interactions and additional regulation within the germinal
centre. In addition, EBNA3B plays a role in suppressing the detrimental effects of EBNA3A- and
EBNA3C-mediated oncogenic functions. Because the EBNA3s largely epigenetically reprogram genes,
the regulation of those genes is sustained following the sequential silencing of viral gene expression
during germinal centre transition. This ensures the memory B cell pathway is favoured during latency
progression, but it is possible that long-term effects may contribute to the prevalence of EBV-associated
cancers. The complex essential roles of EBNA3A, EBNA3B and EBNA3C within EBV infection thus
appear to be delicately balanced, allowing this potent oncogenic virus to achieve ubiquitous and
life-long latent infection in the worldwide population.
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